Considering the lack of reliable brain-related biomarkers of MPS and ongoing clinical trials, this study demonstrates that the determination of the CSF levels of NP1, Ch3L1, CD14, IGFBP2, possibly also of other upregulated proteins identified here could be helpful for assessing the course of the disease in infants having received gene therapy. Here, CD14 is linked to mucopolysaccharidosis.